Skip to main content

Table 2 Initial treatment regimens of 90 anti-MDA5 positive patients

From: Initial predictors for short-term prognosis in anti-melanoma differentiation-associated protein-5 positive patients

Variables (n = 90) Value
Initial combination therapy, n (%) 58 (64.4)
High dose GC + CNI, n (%) 30 (30.0)
High dose GC + CYC, n (%) 21 (23.3)
High dose GC + CNI + CYC, n (%) 7 (7.8)
Step-up therapy, n (%) 32 (35.6%)
Additional treatment  
IVIG, n (%) 43 (47.8)
Hemodialysis 2 (2.22)
  1. anti-MDA5, anti-melanoma differentiation-associated protein-5; GC, glucocorticoid; CNI, calcineurin inhibitors; CYC, cyclophosphamide; IVIG, intravenous immunoglobulin